Budget IMPACT MODEL of the Dexamethasone Intravitreal Implant in Applicator
Author(s)
Crocchiolo D, Donnini N, Formica D
Allergan, an AbbVie company, Roma, RM, Italy
OBJECTIVES : To estimate the economic impact following the introduction of dexamethasone intravitreal implant (700 μg; DXI) for treatment of diabetic macular oedema (DMO) from the Italian National Health System (NHS) perspective. METHODS : This model-based analysis compared two health impact scenarios: a baseline scenario that considers the current market shares of anti-vascular endothelial growth factor (VEGF) agents and a scenario that provides for greater use of DXI. From the population ≥50 years of age residing in Italy on January 1, 2019, identified from the Italian National Institute of Statistics (ISTAT) database, those with diabetic pathology (N= 1,457,031; 5.4%) and with reduced visual capacity (N= 99,078; 6.8%) were selected. The analysis was conducted in patients diagnosed with DMO and eligible for intravitreal therapy (N= 24,770; 25.0%). Market shares of drug therapies (excluding bevacizumab) were obtained from the IQVIA database (Moving Annual Total to March 2019). The number of injections of each anti-VEGF agent was estimated according to treatment schedules in the Summary of Product Characteristics or clinical trials, and parameterized based on the time horizon of analysis. For each agent, a minimum and maximum range of administration frequencies was reported. Direct drug treatment costs (acquisition and administration) were considered. RESULTS : Assuming an incremental treatment rate of 1,000 patients/year with DXI compared with ranibizumab, the most frequently used anti-VEGF nationally, the estimated annual saving ranged from 2.8% (- €3,708,300) at the simulated minimum administration frequency to 4.8% (- €7,942,400) at the simulated maximum treatment frequency. The resources released would allow treatment of 759 to 1,293 new patients over 12 months, with the potential benefit of reduced waiting lists. CONCLUSIONS : The results show that incremental use of DXI is associated with significant economic advantages in both simulations, with estimated cost savings being directly proportional to its degree of market penetration.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PDG22
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders